

Pharmaceutical Pipeline Submission Guidelines

Pharmaceutical Pipeline submission should include those with early clinical data (Phase 1 and 2) on compounds for which Phase 3 data had not been presented. The goal was to generate enthusiasm for the many novel compounds under exploration, most of which have not reached Phase 3. This is not to exclude presentations of clinical data on compounds currently in Phase 3 targeted to truly untested mechanisms since such data would also be of great interest.